cyn-3 Antibody
Description
Overview of Cy3 and Anti-Cy3 Antibodies
Cyanine dyes like Cy3 are sulfonated indocyanine dyes with high quantum yield and photostability, enabling sensitive detection in fluorescence microscopy, flow cytometry, and Western blotting . Anti-Cy3 antibodies specifically recognize the Cy3 fluorophore, allowing researchers to detect or localize Cy3-labeled probes in biological systems.
Key Applications
-
Immunofluorescence (IF): Visualization of Cy3-conjugated primary antibodies in fixed cells .
-
Western Blot (WB): Detection of biotinylated proteins via Cy3-streptavidin complexes .
-
Immunoprecipitation (IP): Isolation of Cy3-tagged protein complexes .
Fluorescence Imaging
In ICC/IF assays, anti-Cy3 antibodies (e.g., ab228690) enable high-resolution imaging of microtubule-organizing centers in human lung carcinoma cells (A549 line) when paired with Hoechst 33342 nuclear counterstain .
Enhanced Signal Detection
Biotin-Cy3 systems amplify signals by binding multiple streptavidin molecules (each carrying 5+ fluorophores) to a single biotinylated antibody, improving detection sensitivity in low-abundance targets .
Comparative Performance in Diagnostic Assays
While not directly tested for Cy3, related studies highlight the importance of antibody specificity:
-
CBA vs. ELISA/RIPA: Cell-based assays (CBA) show 8–10% higher specificity than ELISA or RIPA for detecting low-affinity antibodies .
-
Cross-Adsorption: Anti-Cy3 antibodies are cross-adsorbed against serum proteins from multiple species to reduce background .
Limitations and Considerations
-
Endogenous Biotin Interference: Biotin-rich tissues (e.g., liver) may require blocking steps when using biotin-Cy3 systems .
-
Photobleaching: Cy3 signals degrade under prolonged illumination; antifade mountants are recommended .
Future Directions
Recent advances in recombinant antibody engineering (e.g., Superclonal™ technology) aim to improve anti-Cy3 specificity and reduce batch variability . Additionally, Cy3-linked immunotoxins are being explored for targeted cancer therapy .
Product Specs
Constituents: 50% Glycerol, 0.01M Phosphate Buffered Saline (PBS), pH 7.4
Target Background
Q&A
FAQs for Researchers on Cynomolgus TIM-3 (Cyn-3) Antibodies in Academic Research
How do I validate the specificity of anti-Cyn-3 antibodies for flow cytometry applications?
To ensure specificity, use a multi-step validation workflow:
-
Competitive blocking assays: Pre-incubate antibodies with recombinant Cyn-3 protein to confirm signal reduction (e.g., ≥95% reduction in MFI) .
-
Cross-reactivity testing: Validate against related proteins (e.g., human/mouse TIM-3, PD-L1) using ELISA or Octet bio-layer interferometry (BLI). For example, MsT001 anti-Cyn-3 showed <5% binding to human CD137 or OX40 .
-
Cell line panels: Test antibody binding on Cyn-3-expressing vs. knockout cell lines. A validated example:
What clonality (monoclonal vs. polyclonal) is optimal for Cyn-3 epitope mapping?
-
Monoclonal antibodies (e.g., MsT065) are preferred for single-epitope resolution, with minimal batch variability. They achieve sensitivities ≤10 pg/mL in ELISA .
-
Polyclonal antibodies may detect multiple epitopes but risk cross-reactivity. For structural studies, use recombinant monoclonals engineered for defined paratopes .
How do I design ELISAs to quantify Cyn-3 antibody affinity?
-
Direct ELISA: Coat plates with Cyn-3-hFc (1 µg/mL), apply serial antibody dilutions (0.1–100 nM), and measure OD450.
-
Octet BLI: Immobilize Cyn-3-hFc on AHC sensors, then measure association/dissociation rates. Example affinity data:
How do I resolve discrepancies in Cyn-3 antibody performance across species?
-
Epitope alignment: Use Clustal Omega to compare Cyn-3 vs. human/mouse TIM-3 sequences. For example, the MsT286 epitope (residues 120–135) has 89% homology to human TIM-3 but only 62% to mouse .
-
Functional assays: Compare ligand blockade (e.g., galectin-9 inhibition) across species. Antibodies showing <20% cross-reactivity in BLI may require species-specific optimization .
What in vivo models are suitable for testing Cyn-3 antibody durability?
-
AAV-mediated delivery: Intramuscular injection of AAV8 vectors encoding anti-Cyn-3 antibodies achieves sustained serum concentrations (>1 µg/mL for 3 years post-injection) in primates .
-
Persistence metrics: Monitor serum half-life (t<sub>½</sub>) via PK modeling and anti-drug antibody (ADA) responses using bridging ELISAs. ADA-positive subjects show 50–70% reductions in antibody titers .
How can I assess Cyn-3 antibody neutralization potency in HIV-1 studies?
-
PT<sub>80</sub> biomarker: Calculate the serum dilution required for 80% viral neutralization. For HIV prophylaxis, a PT<sub>80</sub> >200 against circulating isolates correlates with 90% efficacy .
-
TZM-bl pseudovirus assay: Measure IC<sub>50</sub> against Cyn-3-sensitive HIV strains. Example neutralization data:
What computational tools improve Cyn-3 antibody affinity/specificity balancing?
-
Machine learning-guided optimization: Train models on BLI datasets (e.g., association rates, K<sub>D</sub>) to predict mutations enhancing affinity without off-target binding. For emibetuzumab analogs, this reduced non-specific binding by 40% .
-
Epitope binning: Use SPR or hydrogen-deuterium exchange (HDX-MS) to map competing antibodies and engineer non-overlapping paratopes .
